Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,600
Views
9
CrossRef citations to date
0
Altmetric
Author's View

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study

Paolo A. Asciertoa Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”, Napoli, ItalyORCID Iconhttps://orcid.org/0000-0002-8322-475XView further author information
ORCID Icon,
Francesco M. Marincolab Refuge Biotechnologies, Menlo Park, CA, USAView further author information
,
Bernard A. Foxc Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA;d Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USAView further author information
&
Jérôme Galone Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;f Equipe Labellisée Ligue Contre le Cancer, Paris, France;g Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9635-1339View further author information
ORCID Icon
Article: 1826132 | Received 14 Sep 2020, Accepted 16 Sep 2020, Published online: 13 Oct 2020

References

  • Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. doi:10.1038/s41568-020-0285-7. PMID: 32753728.
  • Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology. 2014;3:e27456. doi:10.4161/onci.27456. PMID: 24800163.
  • Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–4. doi:10.1007/s00281-011-0264-x. PMID: 21461991.
  • Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84:981–987. doi:10.1189/jlb.1107773. PMID: 18559950.
  • Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26:332–339. doi:10.1158/1078-0432.ccr-18-1851. PMID: 31413009.
  • Galon J, Bruni D. Tumor Immunology And Tumor Evolution: Intertwined Histories. Immunity. 2020;52:55–81. doi:10.1016/j.immuni.2019.12.018. PMID: 31940273.
  • Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. PMID: 27121213.
  • Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. doi:10.1016/S0140-6736(18)30789-X. PMID: 29754777.
  • Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;JCO1903205. doi:10.1200/JCO.19.03205. PMID: 32897827.
  • Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, et al. Contribution of immunoscore and molecular features to survival prediction in stage III colon cancer. JNCI Cancer Spectr. 2020;4:pkaa023. doi:10.1093/jncics/pkaa023. PMID: 32455336.
  • Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31:921–929. doi:10.1016/j.annonc.2020.03.310. PMID: 32294529.
  • Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2013;2:e26621. doi:10.4161/onci.26621. PMID: 24498550.
  • Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. doi:10.4161/onci.1.2.19026. PMID: 22720239;. 2011ONCOIMM0105. .
  • Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2013;2:e23510. doi:10.4161/onci.23510. PMID: 23687621.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.